LYONS GARY A — SEC insider filings
SEC reporting owner CIK 1123343. 44 insider filings on record with FilingPulse; latest filed 2026-11-19.
Transaction summary — filings shown
Covers all 44 filings on record, filed 2020-09-02 to 2026-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 27 legs across 18 filings — 190,000 shares, $18,331,274 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 75.
- Largest priced transaction: sale of 15,000 shares @ $152.61 ($2,289,082) in NEUROCRINE BIOSCIENCES INC, filed 2025-12-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Director | 23 | — | 19 legs · 132,000 sh · $16,780,767 | 36 |
| Travere Therapeutics, Inc. (TVTX) | Director | 9 | — | 8 legs · 58,000 sh · $1,550,507 | 20 |
| Brickell Biotech, Inc. (BBI) | Director | 5 | — | — | 9 |
| RIGEL PHARMACEUTICALS INC (RIGL) | Director | 3 | — | — | 6 |
| Eledon Pharmaceuticals, Inc. (ELDN) | Director | 4 | — | — | 4 |
Insider filings — LYONS GARY A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 15,000 @ $53.64 · Sale (S): 1,200 @ $163.11 · Sale (S): 4,011 @ $163.94 · Sale (S): 5,689 @ $165.15 · Sale (S): 4,100 @ $165.90 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 5,000 @ $17.44 · Sale (S): 1,900 @ $62.53 · Sale (S): 2,600 @ $63.50 · Sale (S): 500 @ $64.16 · Option exercise (M): 5,000 @ $17.44 · Sale (S): 4,100 @ $63.27 · +3 more | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 1,284 (derivative) @ $0 · Grant/award (A): 2,624 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,659 @ $0 · Option exercise (M): 1,659 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 @ $16.33 · Sale (S): 8,000 @ $41.07 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 15,000 @ $47.89 · Sale (S): 15,000 @ $152.61 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,435 @ $0 · Grant/award (A): 1,659 (derivative) @ $0 · Grant/award (A): 3,305 (derivative) @ $0 · Option exercise (M): 1,435 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 40,000 @ $10.48 · Sale (S): 21,179 @ $14.35 · Sale (S): 18,821 @ $15.15 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-08-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 11,570 @ $42.76 · Sale (S): 11,570 @ $150.43 · Option exercise (M): 11,570 (derivative) @ $0 | EDGAR |
| 2024-07-18 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 930 @ $42.76 · Sale (S): 930 @ $150.03 · Option exercise (M): 930 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 1,435 (derivative) @ $0 · Grant/award (A): 2,982 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,100 @ $0 · Option exercise (M): 2,100 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 12,500 @ $42.76 · Sale (S): 12,500 @ $135.63 · Option exercise (M): 12,500 (derivative) @ $42.76 | EDGAR |
| 2024-05-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2023-12-27 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 10,000 @ $130.04 | EDGAR |
| 2023-12-05 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,000 @ $12.98 · Sale (S): 5,000 @ $116.77 · Option exercise (M): 5,000 (derivative) @ $12.98 | EDGAR |
| 2023-09-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,000 @ $12.98 · Sale (S): 5,000 @ $115.02 · Option exercise (M): 5,000 (derivative) @ $12.98 | EDGAR |
| 2023-09-06 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,000 @ $12.98 · Sale (S): 5,000 @ $110.06 · Option exercise (M): 5,000 (derivative) @ $12.98 | EDGAR |
| 2023-07-12 | 4 | RIGEL PHARMACEUTICALS INC (RIGL) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,500 @ $0 · Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 4,290 (derivative) @ $0 · Grant/award (A): 2,100 (derivative) @ $0 | EDGAR |
| 2023-05-02 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) | Grant/award (A): 150,437 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 15,000 @ $12.71 · Sale (S): 15,000 @ $114.76 · Option exercise (M): 15,000 (derivative) @ $12.71 | EDGAR |
| 2022-10-05 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 5,000 @ $110.54 | EDGAR |
| 2022-05-23 | 4 | RIGEL PHARMACEUTICALS INC (RIGL) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 9,724 (derivative) @ $0 | EDGAR |
| 2022-05-17 | 4 | Brickell Biotech, Inc. (BBI) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2022-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 3,000 @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2022-04-27 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 15,000 @ $6.66 · Sale (S): 15,000 @ $92.76 · Option exercise (M): 15,000 (derivative) @ $6.66 | EDGAR |
| 2022-02-02 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-10-12 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 5,000 @ $105.06 | EDGAR |
| 2021-06-14 | 4 | Brickell Biotech, Inc. (BBI) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 10,000 @ $100.27 | EDGAR |
| 2021-05-21 | 4 | RIGEL PHARMACEUTICALS INC (RIGL) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 8,833 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 3,000 @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2021-01-27 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,600 @ $120.03 · Sale (S): 400 @ $120 | EDGAR |
| 2021-01-05 | 4 | Brickell Biotech, Inc. (BBI) | Tax withholding (F): 5,967 @ $0.78 | EDGAR |
| 2020-09-17 | 4 | Brickell Biotech, Inc. (BBI) | Grant/award (A): 11,934 @ $0.81 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | Novus Therapeutics, Inc. (NVUS) | Grant/award (A): 1,167.21 (derivative) @ $0 | EDGAR |
| 2020-09-02 | 4 | Brickell Biotech, Inc. (BBI) | Option exercise (M): 692 · Tax withholding (F): 346 @ $0.94 · Tax withholding (F): 8,631 @ $0.94 · Option exercise (M): 692 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1123343 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs